Dietlein M, Schicha H
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, 50924 Cologne.
Nuklearmedizin. 2003 Jun;42(3):80-5.
The discussion in Germany about the reimbursement of the (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in oncology should make use of the experience from the other European countries.
A questionnaire was sent to 23 PET-institutions in Europe, outside from Germany, in January 2003. The questions were about the number of PET-institutions, the regulations for reimbursement, the accepted indications, the recognized types of PET-machines and the level of reimbursement.
16 PET-institutions from 10 different countries answered. The relation of PET-institutions to inhabitants ranged from 1:500,000 (B) and 1:1,000,000 (D, A, CH) to approximately 1:4,000,000 (I, E, F, NL). In Belgium, the Netherlands, France, Great Britain, Italy, Finland, Switzerland, and Spain reimbursement was possible and a broad spectrum of indications was accepted, respectively. The reimbursement was not restricted to official indications. In Germany and Austria PET was not generally covered for the patients insured by the national health insurance. An annual sum of approximately 450,000 euro was granted to the recognized PET-institutions in Belgium and France. In Denmark the clinics and their PET-centres were owned by the government, PET was part of the clinical routine oncology. If PET was separately covered the average level of reimbursement for the whole-body PET using a full-ring detector was 1200 euro. The reimbursement of the coincidence-gammacamera differed from the "dedicated" PET in most European countries.
In Europe there is an increasing tendency to cover the well documented PET indications in oncology.
德国关于肿瘤学中（18）F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）报销的讨论应借鉴其他欧洲国家的经验。
2003年1月向德国以外的23家欧洲PET机构发送了一份调查问卷。问题涉及PET机构的数量、报销规定、认可的适应症、认可的PET机器类型以及报销水平。
来自10个不同国家的16家PET机构进行了回复。PET机构与居民的比例从1:500,000（比利时）和1:1,000,000（丹麦、奥地利、瑞士）到约1:4,000,000（意大利、西班牙、芬兰、荷兰）不等。在比利时、荷兰、法国、英国、意大利、芬兰、瑞士和西班牙，报销是可行的，并且分别接受了广泛的适应症。报销不限于官方适应症。在德国和奥地利，国家医疗保险覆盖的患者一般不包括PET检查。比利时和法国每年向认可的PET机构提供约450,000欧元的资金。在丹麦，诊所及其PET中心归政府所有，PET是临床肿瘤学常规的一部分。如果PET单独报销，使用全环探测器的全身PET的平均报销水平为1200欧元。在大多数欧洲国家，符合探测伽马相机的报销与“专用”PET不同。
在欧洲，越来越倾向于涵盖肿瘤学中有充分记录的PET适应症。
